News

ThromboGenics, a biotechnology company, has completed patient enrollment for a Phase II trial of microplasmin intravitreal injection for the treatment of diabetic macular edema. According to the company,

Proteon Therapeutics, a biopharmaceutical company, has successfully completed a $38m series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund.

Financial Highlights Reported revenues up 27.8% to GBP85.3 million (2007: GBP66.7 million); constant currency revenue growth of 14.3% Point-of-care (PoC) Division revenues up 37.4% to GBP34.3 million (2007:

Schering-Plough has received both the European Commission and the FDA approvals for the intravenous formulation of temozolomide as an alternative to the already approved oral form of the

For the fourth quarter of 2008, Neoprobe had a net loss of $1.2 million or $0.02 per share compared to a net loss of $1.9 million or $0.03

Prior to joining Biolase, Mr Capallo spent 10 years as director of corporate accounting for Irvine-based Interpore International, a manufacturer and distributor of orthopedic products including spinal implants,

Mr Buckley joins Neugenesis from Genitope, where he was former vice president of manufacturing. Prior to that, he was vice president-Bexxar operations for the Corixa. Dorsey Stuart, chairman

Mr Prondzynski brings strong executive management and diverse global experience from leadership positions held at multinational healthcare companies. The addition of Mr Prondzynski expands Hospira’s board to 10

Mr Przybyl is replacing Tom Anderson, Ani’s founding CEO, who is leaving to pursue other opportunities. Mr Anderson will remain on Ani’s board of directors. Most recently, Mr